Benzinga
26 Feb 2026, 21:06 UTC · 33w ago
Verdict
Headline takes no side. We score AUPH −0.40 across four claims — moderately bearish.
−0.40moderately bearish
More negative than 71% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Aurinia Pharmaceuticals provided 2026 total revenue guidance of $315 million to $325 million, which is below the Wall Street consensus of roughly $327 million.
More negative than 94% of claims this week
The company reported Q4 2025 adjusted earnings of $0.26 per share and revenue of $77.1 million, beating consensus estimates of $0.22 and $74.8 million respectively.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 80% of claims this week
Aurinia repurchased 12.2 million shares for $98.2 million and maintains a cash position of $398 million.
So whatSignificant share buybacks reduce float and increase shareholder value, while a strong cash balance supports future R&D and stability.
More positive than 68% of claims this week
The company is advancing its autoimmune candidate aritinercept into additional clinical studies in 2026.
More positive than 55% of claims this week
Which stocks this story touches
More negative than 71% of ticker scores this week
The stock price dropped due to forward revenue targets coming in below Wall Street consensus, despite a strong quarter.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The Motley Fool
12m ago
+21.0%
Price is moving against the score
$16.90 vs $13.97 close before publication (Feb 26) · not market-adjusted
AUPH chart →
